Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial

Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis

(2019) Taesik Gwag et al.   JOURNAL OF HEPATOLOGY

A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver

(2019) Christina Preuss et al.   Cells

An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

(2019) Shi-Hui Law et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients

(2019) Mika Hilvo et al.   EUROPEAN HEART JOURNAL

Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons

(2019) Emily R. Bowman et al.   Frontiers in Immunology

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus

(2018) Fernando Bril et al.   DIABETES OBESITY & METABOLISM

Relationship between serum bilirubin levels and cardiovascular disease

(2018) Sunghwan Suh et al.   PLoS One

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

(2018) Lucia Taramasso et al.   BMC INFECTIOUS DISEASES

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials

(2018) D Hagins et al.   HIV MEDICINE

Changes in plasma lipidome following initiation of antiretroviral therapy

(2018) Janine M. Trevillyan et al.   PLoS One

Coronary Artery Disease Manifestations in HIV: What, How, and Why

(2018) Arjun Sinha et al.   CANADIAN JOURNAL OF CARDIOLOGY

Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis

(2018) Jesus M Banales et al.   HEPATOLOGY

Novel Lipidomic Biomarkers in Hyperlipidemia and Cardiovascular Diseases: An Integrative Biology Analysis

(2017) Sneha Rai et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Cardiovascular disease in patients with HIV

(2017) Flavia Ballocca et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

(2016) Pornpimol Thamrongwonglert et al.   HIV CLINICAL TRIALS

Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz

(2016) Dhwanil A. Dalwadi et al.   PHARMACOLOGICAL RESEARCH

Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV

(2016) Amedeo Lonardo et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Enhancing metabolomics research through data mining

(2015) Ibon Martínez-Arranz et al.   Journal of Proteomics

Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis

(2015) O.A. Akerele et al.   MEDICAL HYPOTHESES

Stress, the Stress System and the Role of Glucocorticoids

(2015) Nicolas C. Nicolaides et al.   NEUROIMMUNOMODULATION

Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis

(2015) Takhar Kasumov et al.   PLoS One

Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis

(2014) Georg Behrens et al.   AIDS PATIENT CARE AND STDS

Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials

(2014) Pablo Tebas et al.   CLINICAL INFECTIOUS DISEASES

HIV infection and cardiovascular disease

(2014) L. G. Hemkens et al.   EUROPEAN HEART JOURNAL

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz

(2014) A. Blas-Garcia et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Plasma Lipidomic Profiling of Treated HIV-Positive Individuals and the Implications for Cardiovascular Risk Prediction

(2014) Gerard Wong et al.   PLoS One

Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors

(2013) Edana Cassol et al.   BMC INFECTIOUS DISEASES

Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids

(2013) Matej Orešič et al.   DIABETOLOGIA

Plasma Lipid Composition and Risk of Developing Cardiovascular Disease

(2013) Celine Fernandez et al.   PLoS One

Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population

(2012) Alison J. Rodger et al.   AIDS

Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression

(2012) J. Barr et al.   JOURNAL OF PROTEOME RESEARCH